ClinicalTrials.gg
CompletedNCT04370379Updated Nov 11, 2021

Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients

A Phase 1 interventional study of IBI302 (the first dose level) and IBI302 (the second dose level) in Neovascular Age-related Macular Degeneration, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-11-11.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Enrollment
76th of 91
18 · median 62
Started
2020
with 4 others
Phase 1
20 of 106
5 open now
Registered
38th of 106
by date
Lead sponsor
7 of 106
Innovent Biologics (Suzhou) Co. Ltd.

Among the 106 studies in Macular Degeneration with a site in China, this one is the 76th largest by enrollment of the 91 interventional ones that give a count, is one of 5 that started in 2020, is one of 20 in phase 1, and was the 38th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 106 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

This study is designed for multi-center, open-label, randomized, dose escalation phase I trial to evaluate the safety and tolerability of a multiple dose intravitreal injection of IBI302 in neovascular AMD patients.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion criteria

  1. Male or female patient ≥ 50 yrs. of age.
  2. Active subfoveal or parafoveal CNV secondary to neovascular AMD.
  3. Willing and able to sign form and comply with visit and study procedures per protocol.

Exclusion criteria

  1. Presence of uncontrolled glaucoma in the study eye (defined as IOP≥30mmHg despite the standardized treatment);
  2. Presence of active intraocular or periocular inflammation or infection;
  3. History of severe /allergy to active ingredients or any of the study drug, or fluorescein and povidone iodine;
  4. Participated in any clinical study of any other drug within three months prior to enrollment, or attempted to participate in other drug trials during the study;
  5. Diabetic patients have any of the following conditions:>7.5% when screening;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    low dose of IBI302

    Drug: IBI302 (the first dose level)

  • Experimental
    high dose of IBI302

    Drug: IBI302 (the second dose level)

  • Active comparator
    2mg aflibercept

    Drug: Aflibercept

Interventions

06

What researchers measure

Primary outcomes

  1. Ocular safety, assessed by BCVA, slitlamp examination, ophthalmoscopy, IOP, fundus photography

    Time frame: Baseline to Day140

  2. Incidence of adverse events

    Time frame: Baseline to Day140

Secondary outcomes

  1. Changes in central subfield thickness by OCT compared with baseline

    Time frame: Baseline to Day140

  2. Changes in CNV characteristics and CNV area by FA compared with baseline

    Time frame: Baseline to Day140

  3. Changes in BCVA compared with baseline

    Time frame: Baseline to Day140

  4. Positive rate of anti-drug antibody and neutralizing antibody of IBI302

    Time frame: Baseline to Day140

  5. the area under the drug-time curve from 0 to time t of IBI302

    Time frame: Baseline to Day140

  6. the area under the curve at the time of 0-infinity of IBI302

    Time frame: Baseline to Day140

  7. The peak concentration of IBI302

    Time frame: Baseline to Day140

  8. The peak time of IBI302

    Time frame: Baseline to Day140

  9. Clearance rate of IBI302

    Time frame: Baseline to Day140

  10. Half-life of IBI302

    Time frame: Baseline to Day140

  11. VEGF concentration

    Time frame: Baseline to Day140

  12. Concentration of complement fragments

    Time frame: Baseline to Day140

07

Study locations

1 site
  • Shanghai General Hospital
    Shanghai, Shanghai 200080, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Apr 2021, 11 months.

Of 60 industry-sponsored phase 1 interventional studies under Macular Degeneration, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 11 months is below that.

Counting every sponsor, half of 75 studies reached it within 18 months; a quarter within 10 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2020
First posted
Apr 30, 2020
StartActual
May 28, 2020
Primary completionActual
Apr 30, 2021
CompletionActual
May 8, 2021
Last update
Nov 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04370379
Responsible party
Sponsor
First posted
Apr 30, 2020
Start date
May 28, 2020
Primary completion
Apr 30, 2021
Completion
May 8, 2021
Last update
Nov 11, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI302

Start the discussion